The role of the gut-liver axis in NAFLD (non-alcoholic fatty liver disease) has been examining probiotics and have found some new information on the gut microbiome and how probiotics work in NAFLD. The new information that future research found was quite interesting. It stated that there were about 26 major randomized controlled trials that used probiotics for NALFD that ranged between 20 to 200 individuals in four weeks to 1 year. The laboratory assessments included liver enzymes and anthropometric parameters in the body. Some of the studies added cardiovascular risk factors like C-reactive proteins and lipid profiles as markers for insulin resistance. Furthermore, most of the studies have used a probiotic formulation that includes multiple species, although a few were conducted by using a single strain. What NAFLD does to the body is that it becomes a hepatic consequence of metabolic syndrome. This includes obesity, diabetes, and dyslipidemia. What is interesting about the connection between gut microbiota and NAFLD has been attracting a significant amount of attention in recent years. The data has shown that the gut microbiota can affect the hepatic lipid metabolism while also influencing the balance between pro/anti-inflammatory effectors in the liver.